يحاول ذهب - حر

BioSpectrum Asia - May 2024

استمتع بـUnlimited مع Magzter GOLD

يقرأ BioSpectrum Asia إلى جانب أكثر من 9000 مجلة وصحيفة أخرى من خلال اشتراك واحد فقط

عرض الكتالوج

1 شهر

$14.99

1 سنة $149.99

$149.99

$12/month

(OR)

اشترك فقط في BioSpectrum Asia

هدية BioSpectrum Asia

إلغاء في أي وقت.

(لا يوجد التزامات) ⓘ

إذا لم تكن راضيًا عن الاشتراك، يمكنك مراسلتنا عبر البريد الإلكتروني help@magzter.com خلال 7 أيام من تاريخ بدء الاشتراك لاسترداد كامل المبلغ. نعدك بذلك! (ملاحظة: لا ينطبق على شراء عدد واحد فقط)

الاشتراك الرقمي

الوصول الفوري ⓘ

اشترك الآن لتبدأ القراءة فورًا على موقع Magzter، وتطبيقات iOS، وAndroid، وAmazon.

تم التحقق من الأمان

قسط ⓘ

Magzter هو تاجر معتمد لدى Authorize.Net. معرفة المزيد

في هذا العدد

What’s APAC’s Recipe of Success in CLINICAL TRIALS MARKET?
Asia-Pacific (APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world (RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

New South Wales government injects $5M for critical research to address Silicosis crisis

The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.

1 mins

Singapore approves new asthma indication for GSK's Trelegy Ellipta

GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).

1 mins

What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?

Asia-Pacific APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

10+ mins

How APAC Has Turned into Clinical Trial Behemoth

From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.

3 mins

What Are the Main Challenges of Modern Clinical Trials?

With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.

3 mins

"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"

Lokavant Holdings, a US-based clinical trial intelligence technology company provides clinical trial intelligence that enables study teams to make data-driven decisions, as well as risk-based quality management and monitoring services to pharmaceutical companies and contract research organisations (CROs).

2 mins

"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"

US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.

2 mins

"We are exploring opportunities to collaborate with startups and incubators"

Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has named Padraig McDonnell CEO-elect and Chief Operating Officer (COO), succeeding current President and CEO Mike McMullen.

5 mins

"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"

Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.

5 mins

From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution

Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.

5 mins

اقرأ جميع القصص من BioSpectrum Asia

BioSpectrum Asia Description:

الناشر: MM-Activ-Sci-Tech-Communication

فئة: Business

لغة: English

تكرار: Monthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.

* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.

* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.

* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.

* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.